Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
ICI
Oncolytic virus
TNBC
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
08
2019
revised:
31
12
2019
accepted:
06
01
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive to immunotherapies. We tested whether the oncolytic poxvirus CF33-hNIS-ΔF14.5 could modulate tumor immune microenvironment and make the tumors responsive to the immune checkpoint inhibitor anti-PD-L1. We found that virus infection causes the upregulation of PD-L1 levels on triple-negative breast cancer cells
Identifiants
pubmed: 32158622
doi: 10.1080/2162402X.2020.1729300
pii: 1729300
pmc: PMC7051185
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1729300Subventions
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298865
Oncoimmunology. 2019 Mar 28;8(6):e1581528
pubmed: 31069150
Mol Ther. 2011 Feb;19(2):335-44
pubmed: 21119618
J Transl Med. 2018 Apr 26;16(1):110
pubmed: 29699566
Vet Pathol. 2005 Jul;42(4):405-26
pubmed: 16006601
Methods Mol Biol. 2019;1884:297-315
pubmed: 30465212
Nat Rev Cancer. 2009 Jan;9(1):64-71
pubmed: 19104515
PLoS One. 2016 May 26;11(5):e0156323
pubmed: 27227453
Immunity. 2019 Sep 17;51(3):548-560.e4
pubmed: 31471106
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Clin Cancer Res. 2017 Oct 1;23(19):5869-5880
pubmed: 28679778
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8
pubmed: 20226716
Sci Rep. 2018 Jan 9;8(1):217
pubmed: 29317734
J Natl Cancer Inst. 1953 Apr;13(5):1299-377
pubmed: 13035452
Sci Immunol. 2017 May 19;2(11):
pubmed: 28763795
Blood Adv. 2017 May 08;1(12):753-765
pubmed: 29296719
Cancer Res. 2008 Jun 15;68(12):4882-92
pubmed: 18559536
Clin Cancer Res. 2008 Nov 15;14(22):7358-66
pubmed: 19010851
Oncoimmunology. 2018 Jan 19;7(5):e1421891
pubmed: 29721371
Oncotarget. 2017 May 9;8(19):31347-31354
pubmed: 28430626
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
Mol Ther. 2015 Oct;23(10):1630-40
pubmed: 26112079
BioDrugs. 2019 Oct;33(5):485-501
pubmed: 31321623
Cell Rep. 2018 Dec 11;25(11):3074-3085.e5
pubmed: 30540940
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Dis Model Mech. 2015 Mar;8(3):237-51
pubmed: 25633981
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Oncoimmunology. 2018 Mar 13;7(8):e1442169
pubmed: 30221036
Nat Commun. 2017 Mar 27;8:14754
pubmed: 28345650
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
Cancer Res. 2012 Apr 1;72(7):1651-60
pubmed: 22315352
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
J Immunother. 2010 Sep;33(7):697-705
pubmed: 20664357
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Int J Cancer. 2014 Sep 1;135(5):1238-46
pubmed: 24474587
Cell. 2019 Feb 21;176(5):1240-1240.e1
pubmed: 30794777
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
J Immunol. 2010 Apr 15;184(8):4269-75
pubmed: 20237288
J Clin Invest. 2011 Oct;121(10):3786-8
pubmed: 21965334
Mol Ther. 2011 May;19(5):886-94
pubmed: 21364541
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Mol Ther Oncolytics. 2018 Apr 05;9:22-29
pubmed: 29988465
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Mol Ther. 2007 Sep;15(9):1686-93
pubmed: 17579581
Nature. 2005 Feb 24;433(7028):887-92
pubmed: 15711573
Oncologist. 2011;16 Suppl 1:1-11
pubmed: 21278435
Mol Ther Oncolytics. 2019 Apr 11;13:82-92
pubmed: 31061881
Cancers (Basel). 2011 Oct 13;3(4):3856-93
pubmed: 24213115
Oncology (Williston Park). 2008 May;22(6):614-23; discussion 623, 627-9
pubmed: 18561551
BMC Cancer. 2017 Oct 17;17(1):690
pubmed: 29041905
J Appl Oral Sci. 2014 Jul-Aug;22(4):336-46
pubmed: 25141207
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Curr Opin Immunol. 2018 Apr;51:83-90
pubmed: 29550660
Mol Cancer Ther. 2010 Nov;9(11):2924-33
pubmed: 20978162
Cancer Gene Ther. 2020 Apr;27(3-4):125-135
pubmed: 31209267
Expert Opin Biol Ther. 2011 May;11(5):595-608
pubmed: 21338330
Mol Ther Oncolytics. 2018 Mar 22;9:13-21
pubmed: 29988502
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545